A precision herbicide-resistance reversal technology using photodynamic therapy (PDT) to activate photosensitizer-coupled natural GSTF1 inhibitors, restoring herbicide efficacy in resistant grass weeds such as black-grass, rye-grass, and wild oat while reducing environmental toxicity.
Grass weeds including black-grass, rye-grass, and wild oat have developed resistance to widely used herbicides, creating a major challenge for crop protection. This research targets glutathione-s-transferase phi 1 (GSTF1), a protein identified as a key molecular driver of herbicide resistance in these species. The proposed solution uses photodynamic therapy (PDT) to deliver a precision herbicide synergist: a photosensitizer coupled to a natural GSTF1 inhibitor. When activated by UV light, the photosensitizer enables targeted inhibition of GSTF1, reversing herbicide resistance in grass weeds without the broad environmental toxicity associated with conventional chemical inhibitors such as 4-chloro-7-nitrobenzofurazan.
The technology is at early-to-mid stage development. Proof-of-concept has been demonstrated in cell culture and seedling assays confirming photosensitizer activity and GSTF1 inhibition. Future validation will assess the herbicide-busting effect of the photosensitizer-coupled natural inhibitor in both herbicide-sensitive and herbicide-resistant black-grass populations through imaging and phenotyping, with extension to rye-grass and wild oat. The team is actively seeking funding and support for foliage spray uptake studies to advance the technology toward field application.
Newcastle University is a comprehensive public research university in Newcastle upon Tyne, with broad academic and translational activity. Its city‑centre Newcastle Helix innovation district—developed with Newcastle City Council and Legal & General—co‑locates researchers with companies and hosts national innovation centres to enable fast collaboration. Deep integration with Newcastle upon Tyne Hospitals NHS Foundation Trust, supported by a joint research office, enables streamlined study setup, access to clinical populations, and end‑to‑end clinical translation. Research is backed by competitive funding from UKRI councils, the National Institute for Health and Care Research, major charities, the European Union, and industry. A dedicated technology transfer office supports IP, licensing, spinouts, and knowledge‑transfer partnerships.